Table 1.
Patient characteristics of 13,546 antiretroviral naïve HIV-infected patients in the Antiretroviral Therapy Cohort Collaboration (ART-CC) initiating ART with zidovudine and lamivudine stratified by 3rd drug, 2000 – 2005.
| Overall | EFV | NVP | LPV/r | NFV | ABC | |
|---|---|---|---|---|---|---|
| N (Row %) | ||||||
| Frequency 3rd drug | 13,546 (100) | 3,788 (28) | 2,151 (16) | 2,875 (21) | 2,217 (16) | 2,515 (19) |
| Characteristic by 3rd drug | N (Column %) | |||||
| Male | 9,368 (69) | 2,967 (78) | 1,306 (61) | 2,088 (73) | 1,229 (55) | 1,778 (71) |
| IDU | 1,740 (13) | 492 (13) | 261 (12) | 232 (8) | 321 (14) | 434 (17) |
| Clinical CDC stage C | 2,674 (20) | 848 (22) | 255 (12) | 766 (27) | 443 (20) | 362 (14) |
| Median (IQR) | ||||||
| Age (years) | 38 (31 – 45) | 39 (33 – 47) | 36 (30 – 43) | 38 (32 – 46) | 36 (29 – 44) | 38 (32 – 46) |
| CD4 count (cells/μL) | 218 (104 –329) | 207 (94 – 320) | 260 (171 – 366) | 150 (55 – 264) | 214 (92 – 351) | 251 (163 – 354) |
| HIV RNA (log copies/mL) | 4.9 (4.4 – 5.3) | 4.9 (4.5 – 5.4) | 4.7 (4.2 – 5.1) | 5.1 (4.7 – 5.5) | 4.8 (4.2 – 5.3) | 4.7 (4.2 – 5.1) |
EFV, efavirenz; NVP, nevirapine; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; ABC, abacavir; ZDV, zidovudine; 3TC, lamivudine.